Phaseline

Targets › E6

E6: drug programs, companies and trials

4 programs from 3 companies in 4 trials: 4 Phase 1; Infectious disease, Oncology; next expected readout Mar 2027.

Open in Phaseline: the race on E6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CellidBVAC-E6E7
HPV E6/E7-targeting immunotherapeutic vaccine
E6, E7Phase 1Head and Neck Squamous Cell Carcinoma (HNSCC)Mar 2027
University of Alabama at BirminghamTA-CIN
Recombinant fusion protein vaccine comprised of HPV16 L2, E7, and E6 proteins
E6, E7, L2Phase 1ASC-USDec 2027
University of Alabama at BirminghampNGVL4aCRTE6E7L2
DNA plasmid vaccine encoding HPV16 E6, E7, and L2 antigens
E6, E7, L2Phase 1ASC-USDec 2027
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinspNGVL4aCRTE6E7L2
HPV16 DNA vaccine encoding E6 and E7 antigens with electroporation delivery
HPV16, E6, E7Phase 1Human Papillomavirus Type 16Dec 2027

Conditions

ASC-US (2) Head and Neck Squamous Cell Carcinoma (HNSCC) (1) Human Papillomavirus Type 16 (1)

Modalities

protein or peptide (3), small molecule (1)

Companies

University of Alabama at Birmingham (2) Cellid (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Related targets

E7 (4) L2 (2) HPV16 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.